Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.
Actively Recruiting
Researchers are evaluating de-escalated adjuvant treatment approaches in patients with early-stage endometrial cancer that have either POLE mutations or p53 wildtypeno specific molecular profile NSMP. The study compares new tailored treatments against the usual care, which typically involves surgery followed by analysis of tissue to determine the need for additional radiation or chemotherapy. This phase II trial aims to better understand treatment outcomes based on tumor molecular status. Participants may be enrolled in one of two sub-studies EN10.ARAINBO BLUE for POLE-mutated endometrial cancer and EN10.BTAPER for p53 wildtypeNSMP endometrial cancer. Treatments studied include observation alone, observation with adjuvant radiotherapy using external beam radiation or vaginal brachytherapy delivered through specific devices, and other standard radiation methods. These treatments are delivered following surgical removal of the uterus and ovaries, with treatment starting within 10 weeks post-surgery. During the study, participants will be monitored for pelvic, vaginal, para-aortic, and distant recurrences over a three-year period, as well as survival outcomes up to nine years. Researchers will also assess the impact of molecular classification on fear of cancer recurrence using patient-reported questionnaires. Participants will be followed closely at participating centers through scheduled visits and assessments to track treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are evaluating whether high-dose gabapentin can reduce the need for opioid pain medications in patients undergoing chemotherapy and radiation for squamous cell carcinoma of the head and neck. Oral mucositis, a painful side effect of radiation, often requires opioid treatment which can cause many side effects and long-term use concerns. This phase III trial aims to see if gabapentin can better manage mucositis pain compared to placebo. Participants are randomly assigned to receive either gabapentin or a placebo starting at the eighth radiation treatment. Both groups receive standard chemotherapy, radiation, and pain care. Gabapentin or placebo is given orally once daily on day 1, twice daily on day 2, and three times daily from day 3 onward. Treatment continues until mucositis symptoms improve and other pain medications stop, followed by a gradual dose reduction over 11 days. Blood samples are collected throughout. During the study, participants opioid use, pain levels, and quality of life are regularly assessed. Follow-up visits occur at 4 weeks, 3 months, and 6 months after chemoradiation ends. Researchers monitor pain scores, opioid use duration, adverse effects, feeding tube needs, and other health measures to understand gabapentins impact on pain and treatment outcomes.
Actively Recruiting
Researchers are evaluating a treatment approach for patients with locally advanced cervical cancer that has spread to nearby tissues or lymph nodes. This phase III trial compares the addition of induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before the usual chemotherapy and radiation treatment combined with pembrolizumab, followed by pembrolizumab maintenance. The study aims to determine if adding induction therapy improves progression-free survival and overall survival, while assessing safety and biomarkers related to treatment response. Participants are randomly assigned to one of two groups. One group receives standard chemoradiation with cisplatin and pembrolizumab followed by pembrolizumab maintenance. The other group receives induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before starting chemoradiation and pembrolizumab maintenance. Chemoradiation includes weekly cisplatin, radiation therapy daily for 5 weeks, and brachytherapy treatments. Pembrolizumab is given intravenously at different intervals during the treatment and maintenance phases. Throughout the study, participants undergo various imaging scans such as PET, CT, chest x-ray, and MRI, along with blood sample collections to monitor their condition. Researchers evaluate outcomes including progression-free survival, overall survival, treatment side effects, treatment completion times, and biomarker levels. After completing treatments, participants are followed up every 3 months for 2 years, then every 6 months for 3 more years to monitor long-term effects and disease status.
Actively Recruiting
Researchers are comparing two chemotherapy regimens, mFOLFIRINOX and mFOLFOX, both with or without the immunotherapy drug nivolumab, for treating patients with advanced, unresectable, or metastatic HER2-negative adenocarcinoma of the esophagus, gastroesophageal junction, or stomach. This phase III trial aims to see if mFOLFIRINOX with or without nivolumab improves overall survival compared to mFOLFOX with or without nivolumab. The study also evaluates treatment safety, response rates, and explores biomarkers like PD-L1 combined positive score and cell-free DNA. Participants randomized to one of two groups will receive intravenous chemotherapy every 14 days in cycles up to 12 times. One group receives fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan, with nivolumab given as clinically indicated. The other group receives fluorouracil, leucovorin calcium, and oxaliplatin, also with nivolumab as needed. Throughout the study, patients undergo MRI and CT scans and may have blood samples collected. Nivolumab administration depends on clinical need. During the trial, participants will have regular imaging to monitor tumor status and blood tests to track biomarkers. Patient-reported outcomes on treatment side effects are collected at baseline and during cycles. After treatment, participants are followed every six months for up to three years or until tumor progression or withdrawal. The main outcome measured is overall survival over two years, with additional assessments of progression-free survival, response duration, and safety up to three years.
Actively Recruiting
Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.
Actively Recruiting
Researchers are evaluating new treatments for acute hypoxemic respiratory failure AHRF, a serious lung condition affecting millions worldwide and often leading to death or long-term health issues. This adaptive platform trial tests different interventions across varying severity levels, including non-intubated patients, those on mechanical ventilation, and patients needing extracorporeal life support. The study uses an advanced Bayesian design to efficiently assess multiple therapies and strategies, focusing on improving outcomes for critically ill patients. The trial includes several domains studying various therapies such as ultra-protective ventilation with extracorporeal CO2 removal, different mechanical ventilation strategies, corticosteroid use, and new drug treatments like fludrocortisone and nebulized furosemide. Interventions may involve adjusting ventilator settings, sedation, rehabilitation, or medication dosing over periods ranging from days to weeks. Some domains are observational and collect detailed biomarker and clinical data. The platform allows adding or dropping interventions based on ongoing results, optimizing research efficiency. Participants will undergo regular assessments including physiological and biological measurements, respiratory function tests, and monitoring of clinical outcomes like mortality, ventilator-free days, and organ function scores. Safety and adherence to protocols are closely tracked throughout. The study duration varies by intervention, with some domains enrolling patients over two years and monitoring outcomes up to six months. Participants may experience multiple visits for treatment adjustments, data collection, and follow-up evaluations.
1-10 of 16
1